Do NMPA Approvals Cause Share Prices to Rise?
Shi Yingzi · 07/29/2021
three fourths of stocks to rise on the day of approval.
READ MORE
Feature
Antibody Licensing Deals in China: H1 2021 Summary
Minhua Chu · 07/29/2021
Nineteen antibody deals were closed in H1 2021.
READ MORE
Do NMPA Approvals Cause Share Prices to Rise?
Shi Yingzi · 07/29/2021
three fourths of stocks to rise on the day of approval.
READ MORE
The Chinese Government is Taking Initiatives to En...
editor · 07/19/2021
Improve the system of laws and regulations. Speed up their formulation and revision and advance technical guidelines in an orderly manner.
READ MORE
The Advantages of Getting Breakthrough Therapy Des...
editor · 07/19/2021
On July 1, 2020, the latest Drug Registration Regulations were enacted. This new set of regulations introduced four accelerated procedures for BTDs therapy, conditional approval, priority review and approval, and special approval.
READ MORE
Will China’s Capital Market Get Better in 2021?
Xu Weijia · 07/19/2021
As a weathervane of China Biotech, CES HK Biotechnology Index (CES HK Biotech) roseby 9.51% in January, By comparison, A-shares of the China Securities Medicine Index has been rising at 5.02%, the Shanghai and Shenzhen 300 Index had a growth rate at 2.7% and the Hang Seng Index (HSI) had a 3.87% growth.
READ MORE
News
China Approved its First Cell Therapy
Shi Yingzi · 07/19/2021
On June 22, NMPA green-lighted Yescarta (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory large B cell lymphoma.
READ MORE
NMPA Re-elected as ICH Management Committee Member...
Minhua Chu · 07/19/2021
"The NMPA stands in the international arena with clear goals and intentions and will actively participate in the ICH’s international affairs in the future."
READ MORE
New Regulations for Post-Market Drug Changes Rema...
editor · 07/19/2021
Recently, the National Medical Products Administration issued regulations for post-approval changes in medicinal products (for pilot implementation).
READ MORE
Tracker
Antibody Licensing Deals in China: H1 2021 Summary
Minhua Chu · 07/29/2021
Nineteen antibody deals were closed in H1 2021.
READ MORE
COVID-19 Vaccine Developers Attract Huge Investmen...
Minhua Chu · 07/23/2021
China Biotech Fundraising Tracker: Jun 2021
READ MORE
June Numbers Spike with a Big In-Licensing Deal
Minhua Chu · 07/23/2021
China Licensing Deals Tracker: Jun 2021
READ MORE
China Market Approvals Surge in June
Minhua Chu · 07/23/2021
China Market Approval Tracker: Jun 2021
READ MORE
Do NMPA Approvals Cause Share Prices to Rise?
Shi Yingzi · 07/29/2021
three fourths of stocks to rise on the day of approval.
READ MORE
Copyright © 2016-2021 PharmaDJ .All Rights Reserved.   Suggestions and feedback: Support@PharmaDJ.com   Record/License No.:沪ICP备17054709号-1  
About PharmaDJ | Subscription | Contact Us | Copyright Statement